Univesit catholique de Louvain Laure Bindels, PhD Melle, Belgium - - PowerPoint PPT Presentation

The Belgian Metabolomics Day

Research at the Metabolism and Nutrition Research Group Univesité catholique de Louvain

Laure Bindels, PhD Melle, Belgium September 29, 2017

Platforms for metabolomics at UCL

• MASSMET

– Mass spectrometry of metabolites and compounds of pharmaceutical and biological interest

https://uclouvain.be/en/research-institutes/ldri/massmet.html

• NEST

– Nuclear & Electron Spin Technologies

https://uclouvain.be/en/research-institutes/ldri/nest.html

MASSMET platform

Technologies

• Mass spectrometry analysis:

– Mass spectrometry detection – High resolution accurate mass spectrometry – Molecular formula determination – Mass spectra data analysis

• Chromatography: HPLC, UPLC & GC
• Spectroscopy : UV-Vis spectrophotometry & Fluorescence spectroscopy

Analyses

• Lipidomics (fatty acids, bioactive lipids)
• Quality control of plants and plant extracts
• Essential oils

Contact: Prof. Giulio Muccioli (giulio.muccioli@uclouvain.be)

NEST platform

Technologies

• Pre-clinical MRI and MRS
• EPR spectroscopy and imaging

Analyses

• In vivo anatomical structures with high spatial and temporal resolution
• Metabolism (spectroscopy and spectroscopic imaging)
• Vessels architecture (micro-angiography)
• Free radicals measurements
• Free radicals characterization by spin trapping
• …

Contact: Prof. Bénédicte Jordan (benedicte.jordan@uclouvain.be)

Cancer cachexia

• Up to 80% of cancer patients,

depending of the tumor site

• Reduces quality and length of

life

• May be a cause of cancer

therapy discontinuation

• No valid treatment

Fearon et al., Cell Metab 2012; Fearon et al., Nat Rev Oncol 2013; Argiles et al, Nat Rev Cancer 2014. Giacometti, Walking man

Bindels & Thissen, Clin Nutr Exp 2015

Cancer cachexia

Selected synbiotic approach

• L. reuteri 100-23

D0 D1 D13

†

Bcr-Abl-expressing BaF3 cells

ITF

Bindels et al, The ISME J 2016

Benefits of the synbiotic approach

Bindels et al, The ISME J 2016

BaF

Bcr-Abl

CT BaF BaF-LrI 0.0 0.5 1.0

ND #

mRNA levels (relative expression)

CT BaF BaF-LrI CT BaF BaF-LrI 0.00 0.05 0.10 0.15 0.20 0.35 0.40 0.45 0.50

*

tibialis gastrocnemius

*# * *$

Organ weight (% body weight)

Survival

5 10 15 20 0.0 0.2 0.4 0.6 0.8 1.0 1.2

BaF BaF-LrI p = 0.007 median survival + 2 days Days after BaF injection Fraction survival

Morbidity score

BaF BaF-LrI 1 2 3 4 5

# #

Score

Acetate Propionate Butyrate Acetate Propionate Butyrate Acetate Propionate Butyrate

ITF

P r

• p

i

• n

a t e

CT BaF3 BaF3-ITF

2 4 6

§ µ M

Bindels et al, Br J Cancer 2012; Bindels*, Neyrinck* et al, Plos ONE 2015.

BaF

CT BaF3 BaF3-ITF

. . 5 1 .

§ N D

B c r

• A

b l

m R N A le v e ls (re la tiv e e x p re s s io n )

24 48 72 5.010 6 1.010 7

control propionate 2mM

* *

Number of intact BaF3/w ell

Ongoing work

ITF propionate ? ? RS AXOS ?

• S. Pötgens

Dr M. Sboarina

POS

Production of microbial metabolites?

Sarah Pötgens’s thesis, ongoing Fed or not microbiota

• targeting

foods

NMR metabolomics

11

Poster n° 5

UCL (BE) Prof G. Muccioli Prof J.P. Thissen Prof O. Feron Prof P. Sonveaux Dr P. Porporato Prof J.B. Demoulin Dr V. Havelange Dr Fl. Bindels Katholieke Universiteit Leuven (BE) Dr H. Schoemans Prof J. Maertens INRA AgroParisTech (FR) Prof P. Langella and his team University of Reading (UK) Prof S. P. Claus and C. Leroy Institut Pasteur, Lille (FR) Prof B. Pot and Dr C. Grangette ULG (BE) Dr B. Taminiau Prof G. Daube

Lau Laure Bindels www.uclouvain.be/laure.bindels laure.bindels@uclouvain.be

Prof N. Delzenne Dr A. Neyrinck Prof P. Cani

• S. Pötgens

University of Alberta (CA) Prof J. Walter Dr I. Martinez